A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Women
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Atazanavir; Elvitegravir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms WAVES
- Sponsors Gilead Sciences
- 04 Oct 2018 Status changed from active, no longer recruiting to completed.
- 19 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 13 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2018.